ProMIS Neurosciences (PMN) board of directors has determined to effect a one-for-twenty-five reverse stock split of the Company’s common shares, no par value per share. The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, and the Common Shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on November 28, 2025. The CUSIP number of 74346M505 will be assigned to the Common Shares when the reverse stock split becomes effective. When the reverse stock split becomes effective, every twenty-five issued Common Shares will be combined into one issued Common Share, without any change to the par value per share. This will reduce the number of outstanding Common Shares from approximately 53,811,110 million shares to approximately 2,152,444 million shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences Approves Key Shareholder Proposals
- ProMIS Neurosciences price target lowered to $5 from $6 at Guggenheim
- Promising Advancements in Alzheimer’s Research and Strong Financial Position Support Buy Rating for ProMIS Neurosciences
- ProMIS Neurosciences Reports Increased R&D Costs and Net Loss
- ProMIS Neurosciences reports Q3 EPS (24c) vs 31c last year
